Editorial position
Why we do not provide dosing or sourcing advice
Metabolic Peptides does not provide dosing schedules, titration protocols, reconstitution maths or supplier directories. Here is why — safety, legality, prescription-only medicine rules and our anti-self-experimentation position.
Dosing is a clinical decision, not an editorial one
For licensed medicines, the right dose for an individual depends on indication, comorbidities, interacting medicines, baseline labs and a clinician's judgement. A public-facing website is not the right place to answer that question; the right place is a qualified UK prescriber operating within a regulated clinical setting. We summarise published trial titration schedules where doing so is genuinely educational, and we frame them as evidence-record artefacts, not prescriptions.
Investigational and research-only compounds have no safe public dose
For investigational compounds (retatrutide, cagrilintide, CagriSema, survodutide, pemvidutide, mazdutide, cotadutide and others) authorised research protocols are the only context in which dosing is appropriate. For research-only compounds (AOD-9604, HGH Fragment 176-191, CJC-1295, ipamorelin) there is no regulator-approved human dose. Publishing "suggested doses" for either category would either be wrong by definition or actively dangerous.
Sourcing advice is something we will not do
- We do not list, rank, link to or recommend any supplier, compounding pharmacy, online pharmacy or telehealth service.
- We do not facilitate access to grey-market peptides or counterfeit weight-loss pens. The risks are documented on our grey-market and counterfeit-pen pages.
- For UK-licensed medicines, access is through a qualified UK prescriber and a registered pharmacy. That is the path; we do not run an alternative.
- For institutional laboratory research, we publish a laboratory procurement governance page that frames institutional research-grade procurement without naming or ranking suppliers.
Anti-self-experimentation
Self-experimentation with prescription medicines or research-only peptides carries safety, legal and ethical risks. The risks are not symmetric: a bad decision can produce a serious adverse event whose harm cannot be undone by better information later. We are not the right channel for personal-use guidance.
What we do instead
- Explain what the molecules are, how they work, and what the published trials show.
- Frame the UK regulatory position accurately.
- Distinguish licensed medicines from investigational and research-only compounds without blurring categories.
- Track safety signals, evidence gaps and counterfeit-product risk.
- Point readers to qualified clinical care for individual decisions.